Nirav Niranjan Shah, MD, discussed the analysis of autologous transplantation use in patients with relapsed, chemosensitive DLBCL and how it may become a comparator for other clinical trials.
In a data analysis presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Meeting, investigators analyzed whether the use of autologous stem cell transplant in patients with relapsed, chemosensitive DLBCL should remain the standard of care in the CAR T-cell era.
Based on the results of the analysis, it was suggested that autologous transplantation should remain the current standard of care in this patient population.
In an interview with CancerNetwork®, Nirav Niranjan Shah, MD, of the Medical College of Wisconsin, spoke about how this analysis could potentially be a benchmark for future studies.
So, we hope to publish our analysis and get it into a peer reviewed journal, so that it becomes available and I think this will be a study that becomes a benchmark that can then be used as a comparator for other clinical trials. I think this gives us a very interesting viewpoint of contemporary data, were PET-CT was used, which is often, you know, a lot of older studies don't utilize PET-CT. So, I think this will be a study that's a benchmark and can be used as a comparison to new therapies that are coming down the road. Because, you know, since, you know, 1980s 1990s, autologous transplant has been that standard of care for relapsed aggressive B-cell lymphoma. And this supports that it should remain that. But it's also possible that over time new therapies do improve upon autologous transplant. But I think this trial will be a nice sort of benchmark to use for future studies.